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Arsenic. No other element has such a
complex and variegated past. As early
as 500 B.C. the ancients knew about
arsenic, whose name comes from the
Greek word for potent. Through the
centuries, this “king of poisons” was a
common means of homicide. And yet,
arsenic’s image has not always been so
morbid. People in the Middle Ages
wore arsenic amulets around their
necks to ward off the bubonic plague,
and women in Victorian times applied
arsenic compounds to their faces to
whiten their complexions. Hippoc-
rates, the father of western medicine,
recorded arsenic’s usefulness as a topi-
cal remedy for skin ulcers.
Today, arsenic compounds are still
used for pharmaceutical purposes.
Arsenic trioxide is known for its use in
the treatment of acute promyelocytic
leukemia in patients who are unre-
sponsive to, or have relapsed from,
certain chemotherapy agents. Research
published in the 1 April 2005 issue of
the  Journal of Clinical Oncology sug-
gests that arsenic trioxide may have
therapeutic uses in other malignancies
as well, and that it may be used in com-
bination with other chemotherapy
drugs to expand their benefits.
And yet, no toxicologist would
deny that chronic arsenic exposure
places people at risk for a host of
adverse health effects, from skin and
internal cancers (of the bladder, kid-
ney, liver, lung, colon, uterus,
prostate, and stomach) to diabetes
mellitus and vascular, reproductive,
developmental, and neurological ef-
fects. Studies have shown arsenic to be
a potent endocrine disruptor, altering
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ahormone-mediated cell signaling at ex-
tremely low concentrations. 
Joshua Hamilton, program director of
the Dartmouth College Superfund Basic
Research Program, and colleagues pub-
lished papers on the latter topic in the
March 2001 issue of EHP and the August
2004 issue of Chemical Research in
Toxicology.“ W e   demonstrated this with the
glucocorticoid receptor and subsequently
showed that arsenic has similar effects on
all five steroid receptors,” says Hamilton.
“Furthermore, we recently found similar
effects on other members of the nuclear
receptor signaling family, including
retinoic acid and thyroid hormone recep-
tors.” Since these receptors are central to
so many biological processes, Hamilton
suggests that this may be an important
way by which chronic arsenic exposure
contributes to so many malignancies as
well as nonmalignant diseases.
The noncancer effects of arsenic arise
from both acute and chronic exposures.
Among those symptoms linked with acute
exposure to arsenic-laced well water (typi-
cally containing more than 1,200 micro-
grams per liter [µg/L]) are abdominal pain,
vomiting, diarrhea, muscular weakness and
cramping, pain to the extremities, erythe-
matous skin eruptions, and swelling of the
eyelids, feet, and hands. A progressive dete-
rioration in the motor and sensory respons-
es may also result, finally leading to
shock and death. 
The effects of chronic arsenic
poisoning (also called arsenicosis) are
more complex. Aside from cancer,
these chronic effects include athero-
sclerosis, diabetes, hypertension,
anemia, liver disorders, kidney dam-
age, headache, confusion, peripheral
neuropathy, and a variety of skin
lesions, notably hyperkeratosis, or
thickening of the skin, and both
hypo- and hyperpigmentation. 
Skin lesions are the most com-
mon outward sign of chronic arsenic
exposure, though many dermatologic
symptoms are thought to be mediat-
ed by nutritional factors. Studies
conducted in Taiwan, India, and
Bangladesh have linked high-arsenic
well water with the incidence of both
skin lesions and diabetes in a dose-
responsive pattern. One recent popu-
lation study in West Bengal, India,
published in the March 2003 issue of
Epidemiology, showed that the lowest
peak arsenic ingested by a confirmed
case of arsenic-induced skin lesions
was 115 µg/L. 
Among children, chronic arsenic
exposure has also been reported to
cause adverse effects on the digestive,
respiratory, cardiovascular, and nerv-
ous systems. An article in the Sep-
tember 2004 issue of EHP reported
intellectual impairment occurring
when arsenic in drinking water
exceeded 50 µg/L.
There is evidence that arsenic-
exposed people who are predisposed
to noncancerous skin lesions may be
more vulnerable to other cancers.
“During our long field experience in
West Bengal and Bangladesh we
observed that those who are suffering
from severe keratosis appear more
likely to develop cancer later on,” says
Dipankar Chakraborti, director of
the School of Environmental Studies
at Jadavpur University in Calcutta.
“Not only skin cancer but internal
cancers also may arise in people who
show such noncancerous lesions.” 
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Arsenic concentrations in Bangladeshi tubewells 
Source: British Geological Survey. 2001. Arsenic Contamination of Groundwater in Bangladesh. Available: http://www.bgs.ac.uk/arsenic/bangladesh/reports.htm.
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The lung, too, seems to be a major site
of action of ingested arsenic. “Lung cancer
is the main cause of arsenic-related death,”
says Allan Smith, director of the Arsenic
Health Effects Research Program at the
School of Public Health, University of
California, Berkeley. “But we’re also seeing
many noncancer [lung] effects, such as a
tenfold [increase in the] rate of bronchiecta-
sis in people with skin lesions in India.”
The prevalence and incidence of these
noncancer manifestations of arsenic expo-
sure is highly variable from one country to
the next. For example, whereas skin pig-
mentation and hyperkeratosis are common
indicators of arsenic exposure in Taiwan, it
may be more common in India to see respi-
ratory stress, polyneuropathy, and peripher-
al vascular disease linked with habitual
ingestion of high-arsenic drinking water.
This topic remains a very active area for epi-
demiologic research.
A World Exposed
Globally, millions of people are at risk for the
adverse effects of arsenic exposure. The
majority of harmful arsenic exposure comes
from drinking water from wells drilled
through arsenic-bearing sediments. Drinking
water contains primarily inorganic arsenic,
which is more acutely toxic than the organic
form. The other major sources of arsenic
exposure are through food, soil, and air. For
most people, in fact, the primary exposure to
arsenic comes from food, but dietary arsenic
includes primarily organic forms, which are
relatively nontoxic and contribute little, if
any, to the overall risk associated with
exposure. (Unless otherwise indicated, all
mentions of arsenic in the remainder of
this article refer to the inorganic form.) 
Rebecca Calderon, chief of the Epi-
demiology and Biomarker Branch at the
Environmental Protection Agency (EPA)
National Health and Environmental Effects
Research Laboratory, says that preparing
foods in arsenic-containing water increases
the arsenic content by 10–30% for most
foods, and by 200–250% for beans and
grains, which absorb cooking water. More-
over, arsenic-laced irrigation water can sub-
stantially increase the arsenic content of
rice and vegetables, as recently shown in
several studies in Southeast Asia, including
a February 2005 Chemosphere report on
West Bengal crops and soil.
Soil- and waterborne arsenic does not
readily permeate the skin, though soil can
be a key source of exposure in young chil-
dren who show significant hand-to-mouth
activity. People are also exposed on a more
sporadic basis through a hodgepodge of
human activities, such as the burning of fos-
sil fuels, waste incineration, smelting of
ores, pesticide and herbicide use, coal burn-
ing, semiconductor production, and other
manufacturing processes. The public health
impact of these exposures is largely un-
known as the epidemiologic focus has been
on exposure via drinking water.
For most U.S. citizens who are on piped
water systems, drinking water is not a major
source for arsenic exposure. Nonetheless, in
certain areas in the West, Midwest, South-
west, and Northeast, people drinking well
water may be exposed to arsenic levels rang-
ing from 50 to 90 µg/L, well above the
EPA’s guideline of 10 µg/L. To date, no sta-
tistically significant relationships have been
found between arsenic exposure and cancer
in these areas.
The situation in Bangladesh and West
Bengal is radically different: arsenic expo-
sure through drinking naturally contami-
nated groundwater is widespread and often
excessive. This situation began in the 1970s,
when the United Nations Children’s Fund,
in response to epidemics of cholera, dysen-
tery, and other waterborne infectious dis-
eases, spearheaded an effort to switch the
region’s population from drinking surface
waters to groundwater. Millions of tube-
wells were drilled into arsenic-rich sedi-
ments; as a result, in many of these wells
arsenic levels reach 500–1,000 µg/L and
even higher. 
Field studies have shown that many peo-
ple living in a vast geological zone known as
the Ganga-Meghna-Brahmaputra plain are
being exposed to high arsenic levels in the
water. A large portion of this plain, an area
totaling 500,000 square kilometers and
spanning all of Bangladesh and most of
India, shows significant groundwater
arsenic contamination, putting more than
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Good intentions gone awry. Villagers drill
a tubewell in Bangladesh (left). Encouraged
as a solution to pathogenic contamination of
surface waters, such wells have resulted in
exposure of millions to arsenic, leading to the
need for alternative water sources (above).500 million people at risk of chronic arsenic
poisoning, says Chakraborti. He published
these alarming estimates in the June 2004
issue of the Journal of Environment Mon-
itoring. With 80% of Bangladeshis estimat-
ed to be at risk of arsenic-related diseases,
the World Health Organization (WHO)
has labeled this “the worst mass poisoning
in history.”
Large areas of China also face severe
arsenic exposure from groundwater contam-
ination, with more than 3 million people
affected, based on estimates in the August
2004 issue of Toxicology and Applied
Pharmacology. In Shanxi Province alone, an
estimated 900,000 people are at risk of
arsenicosis. Among the investigated villages
in Shanxi, an average of 52% of wells give
water containing arsenic concentrations
higher than 50 µg/L, according to a recent
report from the School of Public Health at
China Medical University in Shenyang.
A unique type of exposure, resulting
from the burning of arsenic-rich coal, is
found in Guizhou Province, an area of
endemic arsenicosis. Guizhou inhabitants
commonly use this coal for cooking, heat-
ing, and drying their dietary staples of corn
and hot peppers. The coal is burned in
open stoves without chimneys, resulting
in contamination of both the indoor air and
the foods being prepared. At this time,
arsenicosis is known to affect eight provinces,
but most of China has not been studied, and
new endemic areas are continuously emerg-
ing. Reports on arsenicosis in China actually
preceded those from Bangladesh and India,
but have been overlooked due to limited sci-
entific exchange and publication.
Other countries with arsenic-rich
groundwaters include Argentina, Chile,
Mexico, Cambodia, Vietnam, Thailand,
Nepal, and Ghana. In the Obuasi area of
Ghana, arsenic contamination of food and
water has been linked with gold-mining
activities. Much of the gold in the Obuasi
mines is locked in pyrite and arsenopyrite,
both associated with arsenic and sulfur. The
extraction of the gold results in the release of
airborne particles that include large concen-
trations of arsenic. At least 10% of Ghana’s
rural borehole wells have arsenic concentra-
tions exceeding 10 µg/L. In the Terai region
of Nepal, inhabited by half the country’s
total population, hundreds of thousands of
shallow tubewells have been installed by var-
ious agencies, and groundwater is the pri-
mary source of drinking water. According to
Chakraborti, around 500,000 people in
Terai are at risk of arsenic poisoning from
drinking this water, and up to 1 in 20 peo-
ple may show skin lesions indicative of
arsenicosis.
The Arsenic–Cancer Equation
Today, researchers around the world are rac-
ing against the clock to unravel the secrets of
arsenic’s workings, including how it influ-
ences the cancer process and thereby
increases cancer risk. Although inorganic
arsenic is generally held to be more acutely
toxic, some researchers argue that the organ-
ic metabolites of arsenic may be the ultimate
carcinogens. One of these metabolites,
DMA, has been shown in rodents to induce
bladder cancer and to promote tumor
growth in several other organs. A review
article focusing on induced disturbances of
calcium homeostasis, genomic damage, and
apoptotic cell death caused by arsenic and
its organic metabolites appears in the June
2005 issue of EHP.
There is general agreement that arsenic
does not directly interact with DNA, and
that its toxic effects occur through indirect
alteration of gene expression, such as via
the perturbation of DNA methylation,
inhibition of DNA repair, oxidative stress,
and altered modulation of signal transduc-
tion pathways. Many of these mechanisms
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Coal catastrophe. Cyclists on their way to work in Guizhou Province, China, pass through smoke pouring out of a coal-burning cooking stove. Exposure
to the arsenic-rich coal burned in this region has resulted in endemic arsenicosis.Environmental Health Perspectives • VOLUME 113 | NUMBER 6 | June 2005 A 383
are overlapping, interde-
pendent, and heavily
influenced by factors in
the cellular environment.
For example, arsenic pro-
motes both oxidative stress
and impaired DNA repair,
and yet both of these effects
tend to amplify mutation
rates, thus increasing the
likelihood of cancer. 
Another indirect mech-
anism is the influence of
growth-stimulating chemi-
cals or cytokines generated
in response to arsenic expo-
sure. Dori Germolec, a
research scientist at the
NIEHS Laboratory of
Molecular Toxicology, has
been approaching the
arsenic question from the
standpoint of cytokine
biology. “Arsenic alters the
production of inflammato-
ry cytokines and does so
persistently over time,”
Germolec says. “These
effects on cytokines seem
to relate to its effects on the
skin. Arsenic seems to stimulate progenitor
cells that could ultimately be responsible for
tumor formation. This is just one of a num-
ber of mechanisms that has biological plau-
sibility.” Research published in the April
2004 issue of EHP by Toby Rossman, an
environmental science professor and pro-
gram director of the Molecular and Genetic
Toxicology Program at New York Univ-
ersity, has demonstrated similar relation-
ships in animal models as well as in cultured
human cells.
Studies of differences in arsenic metabo-
lism between individuals have led to further
insights—and further questions. The
importance of individual arsenic metabo-
lites in terms of cancer induction is still
being determined. All of the human popu-
lations studied thus far have been found to
methylate inorganic arsenic, but the pat-
terns of arsenic metabolites in urine show
substantial interindividual variation. Within
any given population, individuals differ in
the quantity and distribution of the various
metabolites of arsenic excreted by the kid-
ney. If some happen to excrete more of the
carcinogenic metabolites or are unable to
metabolize arsenic efficiently, they may be
more vulnerable to cancer. This variation
may be affected by a variety of factors,
including dose level, route(s) of exposure,
diet, and the particular type of arsenic to
which the individual is exposed. Polymor-
phisms in genes that code for the enzymes
important in metabolism, such as arsenic
methyltransferase, have also been implicated
as accounting for some of this variability.
No one yet knows how this interindi-
vidual variation in arsenic metabolism actu-
ally affects cancer risk. “This is a difficult
question since when you deal with the car-
cinogenicity of inorganic arsenic you are
dealing with six or more distinct [metabo-
lites],” says H. Vasken Aposhian, a molecu-
lar and cell biology professor at the
University of Arizona. Aposhian is involved
in studies in New England, Mongolia,
Romania, Mexico, and Kazakhstan to iden-
tify unique or abnormal arsenic urine pro-
files in people who develop cancer in areas
of high arsenic exposure. Once studies
reveal which of these metabolites are pro-
moters and/or carcinogens, it will be possi-
ble to better answer the riddle of interindi-
vidual variation in vulnerability to arsenic-
induced effects. 
The metabolite MMAIII presently is
one of the leading candidates as a potential
cancer inducer. If MMAIII turns out to be
carcinogenic, an increased or decreased
amount in the urine might prove useful as a
marker for potential future arsenic-mediat-
ed cancer.  
In time, the identification of reliable
exposure markers could help identify groups
that may be more susceptible to cancer at
the levels of arsenic exposure typically found
in the United States (less than 50 µg/L). At
the present time, the carcinogenic risk of
such exposures is unclear. Biomarkers would
provide a more detailed picture of individ-
ual arsenic exposure and how the body is
responding to that exposure. “The low-dose
extrapolations used for risk assessment pur-
poses may be subject to error in part because
they are based more on ecologic data than
on individual measures of exposure,” says
Margaret Karagas, an epidemiology profes-
sor at Dartmouth College. “Use of relevant
markers in human tissue samples eventually
may help us sort out the risk at lower levels
of exposure.” 
One practical biological marker identi-
fied by Karagas is toenail clippings, with
arsenic content measured via instrumental
neutron activation analysis. Using this
measure, she and her colleagues reported in
the June 2004 issue of Cancer Causes &
Control on a case–control study in New
Hampshire suggesting an increased cancer
risk associated with moderate arsenic expo-
sure, but only in smokers.
An Emerging Consensus: Arsenic
Does Not Act Alone
Studies such as Karagas’s point to the grow-
ing recognition that arsenic does not always
operate alone. Rather, arsenic appears to
work with other factors to promote cancer,
at least at some target sites. “Animal models
indicate it takes a promoter or some geno-
toxic carcinogen to get arsenic to produce
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Fool’s gold? Gold mining in areas of Ghana such as the Ashanti Goldfields in Obuasi results in the release of airborne
arsenic particles that also have been linked to food and water contamination.skin cancers,” says Michael Waalkes, sec-
tion chief of the Inorganic Carcinogenesis
Section at the National Cancer Institute
Laboratory of Comparative Carcinogenesis,
housed at the NIEHS. “When you always
see this kind of cotreatment effect, it makes
it harder to nail down the precise contribu-
tion of arsenic to the final tumor.”
The classic cofactor in this regard may
be tobacco smoke. “There is mounting evi-
dence of a malignant synergy between
smoking and arsenic,” says Smith. “Smokers
are at an increased risk from arsenic in
drinking water and appear to comprise a
susceptible subpopulation.” A study by
Smith and colleagues, published in the
November 2000 issue of Epidemiology,
found that the relative risk of lung cancer
for Chileans who smoked and had high
arsenic in their water was 32 times that of
nonsmokers with low arsenic concentra-
tions in their water. In contrast, the lung
cancer risk of smokers without arsenic in
their water was about 6 times that of non-
smokers. Similar findings have come from
studies in Taiwan and New Hampshire.
Other cofactors are also gaining atten-
tion. Rossman’s group was among the first
to hypothesize that arsenic requires a car-
cinogenic partner—in their April 2004
EHP article and another in the 1 August
2004 issue of Toxicology and Applied
Pharmacology, they reported finding that
arsenic plus ultraviolet (UV) radiation
exposure led to a dose-related increase in
skin cancers in mice compared with mice
exposed to UV light alone. The tumors in
mice treated with arsenite plus UV light
also appeared earlier and were larger and
more invasive than those in mice exposed
to UV light alone. At the 2004 Third Inter-
national Conference on Comparative Phys-
iology and Biochemistry, Rossman reported
that selenium deficiency also enhanced the
carcinogenic effects of arsenic.
Such insights may carry over to the epi-
demiological realm. In Bangladesh and
West Bengal, for example, the most likely
cofactors for arsenicosis include malnutri-
tion (with resulting deficiency of selenium
and other nutrients that can affect arsenic
metabolism) and agricultural activities that
lead to frequent sun exposure. Not only
does selenium seem to help protect against
the toxic effects of chronic arsenic expo-
sure, but high levels of chronic arsenic
ingestion from well water may accelerate
the excretion of selenium, according to
research published in the 5 May 2004 issue
of Science of the Total Environment. 
“We need to find out whether Ban-
gladesh and other poverty-stricken coun-
tries with arsenic-tainted groundwater may
benefit by this relatively cheap strategy of
supplementing the diet with selenium,”
says Floyd Frost, an epidemiologist at the
Lovelace Respiratory Research Institute in
Albuquerque. “We need solutions that are
cheap and doable. If you’re in Bangladesh,
there just isn’t much money for expensive
mitigation strategies.” 
However, Smith notes that he and col-
leagues found only modest increased risks in
West Bengal with some dietary deficiencies.
He and others contend that the top priority
should be to reduce arsenic exposure. Other
approaches being explored include rainwater
collection, novel filtration systems, chela-
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Arsenic concentrations across the United States . . . 
Source: USGS, http://water.usgs.gov/nawqa/trace/pubs/geo_v46n11/fig3.html
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tion, and deep community wells, as well as
the use of antioxidants, methionine (an
amino acid), and other dietary supplements
that may limit arsenic’s toxicity. [For more
information on remediation strategies, see
“Columbia Center Digs Deeper into Arsenic
Dilemma” and “Metal Attraction: An Iron-
clad Solution to Arsenic Contamination?” p.
A374 and A398 this issue.]
A Special Population: The Very
Young
Infants and children are deemed to be
more susceptible than adults to the adverse
effects of arsenic and other toxic sub-
stances. Chakraborti has observed that
arsenical skin lesions show up sooner in
children than they do in adults. If the
child’s nutrition is poor, outward signs of
arsenic toxicity manifest even sooner and
at less extreme levels of exposure. An addi-
tional concern is the potential for increased
sensitivity of children to arsenic-associated
neuropsychological effects such as reduced
verbal IQ scores, as reported in the
September 2004 issue of EHP. 
Chakraborti speculates that infants and
children may be intrinsically more suscepti-
ble than adults due to differences in metabo-
lism, a view supported by some preliminary
studies. “In one of our studies on an arsenic-
affected population in Bangladesh, we found
that the second step in arsenic metabolic
pathways is more active in exposed children
in comparison with exposed adults,” he says.
In the June 2005 issue of EHP, Maria
Mercedes Meza and colleagues identified a
developmentally restricted component of
arsenic metabolism, a genetic association
with urinary arsenic metabolites that applied
only to children.
Complicating this scenario is the special
threat posed by in utero exposure to arsenic.
One of the concerns here is that low-level
exposures may have a greater impact if
experienced in utero than if experienced in
childhood or adulthood. Waalkes and his
colleagues were the first to identify the
transplacental carcinogenic potential of
arsenic. They duplicated this finding in sev-
eral rodent studies, reported in the 1
August 2004 issue of Toxicology and
Applied Pharmacology and the 20
May 2004 issue of Toxicology. 
“The critical window of expo-
sure for mice equates to about the
middle three months of pregnan-
cy in humans,” says Waalkes.
“This could lead to a fifty percent
increase in the risk of hepatocel-
lular carcinoma for adults. This is
a reproducible phenomenon, and
it has alarming implications for
in utero exposures in humans.”
The first half of fetal develop-
ment is a period of very high sen-
sitivity because of a high rate of
cell proliferation, cell differentia-
tion, and gene imprinting, all of
which, when disrupted, can lead
to carcinogenesis.
Smith’s studies of bladder and
lung cancers also have indicated
that there may be a long latency—
40 years or more for these can-
cers—from arsenic exposure to
the manifestation of malignant
disease. For example, he has
found very high lung cancer risks
in Chilean adults who were
exposed as children or in utero. He
notes that it is critically important
to study large populations with
significant and well-documented
arsenic exposure. Smith says Chile
has the best-documented expo-
sure in the world. 
“In any country where people
are exposed to high levels of
arsenic, if nothing else is done,
they should focus on protecting pregnant
women, providing them with low-arsenic
water,” says Waalkes. “That would be my
top priority if I could advise the govern-
ments of those countries on what to do.”
How Much Protection Is Enough?
Although the effects of severe arsenic con-
tamination are well established, there is
much debate about the risk associated with
chronic ingestion of drinking water that
contains arsenic levels lower than regulato-
ry standards. The WHO adopted a stan-
dard of 10 µg/L in 1993. Bangladesh and
many other developing countries use a
guideline of 50 µg/L. Beginning in January
2006 the maximum contaminant level for
inorganic arsenic permitted in U.S. drink-
ing water will be 10 µg/L, although scien-
tists still debate this standard. 
Part of the uncertainty regarding the 10
µg/L standard stems from the absence of
epidemiologic data to help determine the
exact shape of the dose–response curve,
particularly at exposures under 10 µg/L.
Cancer risks at these levels of exposure may
be about 1 in 300 people, according to the
National Research Council report Arsenic
in Drinking Water: 2001 Update. However,
says Smith, epidemiology will never prove
such risks are real. He points to the fact
that large numbers of studies throughout
the world were required to eventually
demonstrate that nonsmokers married to
smokers had an increased risk of lung can-
cer, even though such risk involves about 1
in 100 persons.
Still, some argue that different study
designs and larger sampling will, in time,
provide adequate data to answer the ques-
tion of whether there is a level of arsenic
exposure below which health effects do not
develop. In the interim, the precautionary
principle holds sway; policy makers assume
that the burden of proof for potentially
harmful actions or policies rests on the
assurance of safety, and that when there are
threats of cancer or other serious diseases,
scientific uncertainty must be resolved in
favor of prevention.
Acceptance of the limitations of epi-
demiologic research in detecting the risk
associated with low-level exposures lies at
the very heart of this principle. “It is possi-
ble that the effects may be nonlinear, with
certain extremely low levels of arsenic expo-
sure posing no excess risk,” says Karagas.
“In epidemiologic studies, however, it is
important to distinguish between ‘no effect’
and ‘inability to detect an effect’ due to var-
ious methodological limitations.”
There is also, she says, a critical need
for further data on other health outcomes
and in potentially susceptible subgroups
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and those particularly at risk due to
genetic or lifestyle factors. By studying
the whole population but not susceptible
subgroups, scientists may be missing key
pieces to the arsenic puzzle.
Hamilton concurs but emphasizes a
more mechanism-based rationale. He theo-
rizes that arsenic at different doses may act by
different mechanisms, perhaps producing
different patterns of disease. For example, the
patterns of disease in areas such as
Bangladesh that have high and endemic
arsenic contamination may be quite different
than the patterns seen at the lower doses
encountered elsewhere. “We have observed
an almost completely nonoverlapping pat-
tern of gene expression changes with a low
versus a high dose of arsenic, almost as if they
were two different agents,” says Hamilton. 
“At the lower, noncytotoxic dose,” he
explains, “we saw an approximately equal
number of genes that were increased as were
decreased, whereas at the higher, cytotoxic
dose, virtually all of the significant changes
involved activation of genes.” Most of the
genes in the latter case were members of stress
response and apoptosis pathways. Taken
together with Hamilton’s studies of the
endocrine-disrupting effects of low to mod-
erate arsenic levels, this indicates the impor-
tance of examining arsenic at doses that are
directly relevant to the end point of interest.
On the Threshold of a New
Understanding
A major challenge for future research is the
issue of linking genetic polymorphisms
with arsenic-related disease susceptibility.
“Since arsenic metabolism seems to be a
key to the carcinogenic process, sorting out
these polymorphisms will be important,
but this is extremely difficult to do,” says
Julian Preston, director of the EPA’s
Environmental Carcinogenesis Division
and a member of the committee that pro-
duced  Arsenic in Drinking Water: 2001
Update. “You need to see a very strong
association between a particular polymor-
phism and the cancer end point in order to
establish a link.” To date, a few polymor-
phisms have been identified in an indige-
nous population in Chile that may confer
protection against the carcinogenic effects
of arsenic exposure, but the findings are
only suggestive.
Given that humans appear to be sub-
stantially more sensitive than experimental
animals to arsenic-induced cancers, more
epidemiologic research will be needed to
assess the effects of early-life exposures for
child as well as adulthood cancers.
“Humans remain the most sensitive species
when it comes to understanding the toxic-
ity of arsenic,” says Calderon. “Despite
several attempts to use rodents and other
animal species, those assays and experi-
ments have had limited success in explain-
ing what appears to be a rather unique
response on the part of Homo sapiens to
arsenic. This represents a unique challenge,
and perhaps the keys reside in emerging
areas of genomics, proteomics, or molecu-
lar epidemiology.” Childhood exposure to
arsenic has emerged as a potential regulato-
ry concern. 
Arsenic contamination of drinking
water is among the most awesome envi-
ronmental health challenges of our time.
With hundreds of millions of people
affected in Southeast Asia and elsewhere,
the need for effective arsenic mitigation
strategies has never been greater. Thus the
focus is moving beyond exposure to
include those physiologic variables that
may mediate the effects of exposure and
that correlate with adverse effects in
humans. 
Exposures associated with arsenic due
to cooking and agricultural activities
(including herbicide and pesticide use)
should be explored, along with the identi-
fication and control of other carcinogenic
compounds that may act as cocarcinogens.
Such efforts could, in time, result in pro-
found public health benefits and alleviate
a great deal of suffering. 
For people living in areas where arsenic
exposure is less extreme, the question of
whether arsenic is safe below a certain
dosage level remains central. Many scien-
tists assert that only biological data based
on measurements of the variation in
human metabolic responses to arsenic will
resolve the low-dose controversy. Such data
will pave the way for developing biologi-
cally based dose–response models that
should greatly enhance our understanding
of arsenic’s carcinogenic potential. Only
with persistent inquiry and innovative
investigation will the elemental mystery of
arsenic be solved.
M. Nathaniel Mead
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Focus | Arsenic: A Global Poison
Special victims. New information indicates that children metabolize arsenic differently than adults,
and provides compelling reason to further study the effects of the element in vulnerable populations.